Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing fibrate drug and taurine

A technology of phenoxyaromatic acids and compositions, which is applied in the field of pharmacy and can solve problems such as lack of blood lipids

Active Publication Date: 2009-08-26
SHENZHEN AUSA PHARM CO LTD +2
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] Examining the current clinical medication situation, there is no effective and safe drug for comprehensively controlling dyslipidemia, so it is urgent to develop a blood lipid-lowering drug that can comprehensively reduce LDL-C, TG, and TC levels and increase HDL-C levels , to solve the deficiencies of existing clinical drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing fibrate drug and taurine
  • Composition containing fibrate drug and taurine
  • Composition containing fibrate drug and taurine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 Preparation of Compound Fenofibrate Taurine Tablets (1000 Tablets)

[0038] Formula: Taurine 300g

[0039] Fenofibrate 200g

[0040] Lactose 160g

[0041] Microcrystalline Cellulose 50g

[0042] Sodium carboxymethyl starch 20g

[0043] Low-substituted hydroxypropyl cellulose 20g

[0044] Proper amount of povidone aqueous solution

[0045] Magnesium Stearate 1%

[0046] Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 300g of taurine and 200g of fenofibrate and mix uniformly according to the method of equal increments, add 160g of lactose, 50g of microcrystalline cellulose and 20g sodium carboxymethyl starch, mix uniformly according to the method of equal increments, add 10% povidone The aqueous solution is made into a soft material, granulated with a 20-mesh sieve, dried at 60°C for about 2 hours, granulated with a 20-mesh sieve, and the water cont...

Embodiment 2

[0047] Example 2 Preparation of Compound Bezafibrate Taurine Tablets (1000 Tablets)

[0048] Formula: Taurine 100g

[0049] Bezafibrate 400g

[0050] Lactose 160g

[0051] Microcrystalline Cellulose 50g

[0052] Sodium carboxymethyl starch 20g

[0053] Low-substituted hydroxypropyl cellulose 20g

[0054] Proper amount of povidone aqueous solution

[0055] Magnesium Stearate 1%

[0056] The preparation method was the same as in Example 1, and each of the prepared compound tablets contained 100 mg of taurine and 400 mg of bezafibrate, and the mass ratio was 1:4.

Embodiment 3

[0057] Example 3 Preparation of Compound Taurine Gemfibrozil Tablets (1000 Tablets)

[0058] Formula: Taurine 100g

[0059] Gemfibrozil 400g

[0060] Lactose 160g

[0061] Microcrystalline Cellulose 50g

[0062] Sodium carboxymethyl starch 30g

[0063] Low-substituted hydroxypropyl cellulose 20g

[0064] Proper amount of povidone aqueous solution

[0065] Magnesium Stearate 1%

[0066] The preparation method was the same as in Example 1, and each tablet contained 100 mg of taurine and 400 mg of gemfibrozil in the prepared compound tablet, and the mass ratio was 1:4.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition capable of comprehensively improving blood lipid and insulin resistance state of a body at the same time, and belongs to the field of pharmacy. The composition comprises pharmaceutically acceptable doses of phenoxyaromatic acid drugs (including fenofibrate, bezafibrate, gemfibrozil, etc.) or pharmaceutically acceptable salts thereof, pharmaceutically acceptable doses of taurine and pharmaceutically acceptable carriers or excipients. The present invention also relates to that the composition is used to comprehensively control blood lipids of patients, including reducing total cholesterol (TC), low-density lipoprotein (LDL) and triglyceride (TG), and increasing high-density lipoprotein (HDL); simultaneously the present invention The composition involved can be used to treat metabolic syndrome, synergistically improve the insulin resistance state of the body, and improve the insulin sensitivity index, and its effect is obviously better than that of a single medicine. The present invention also relates to the application of the composition in the preparation of medicines for the treatment of living bodies with dyslipidemia or metabolic syndrome.

Description

technical field [0001] The invention relates to a composition containing phenoxyaromatic acid drugs and taurine, and the application of the composition in preparing medicines for treating dyslipidemia or metabolic syndrome (metabolic syndrome, MS). The present invention belongs to the field of pharmacy. Background technique [0002] Dyslipidemia refers to blood total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) exceeding the normal range and / or high-density lipoprotein cholesterol (HDL-C) below normal range. Dyslipidemia plays a very important role in the occurrence and development of atherosclerosis (AS) and the cardiovascular events (cardiovascular events, CVE) caused by it. one of the fastest growing fields. [0003] More and more research results show that dyslipidemia is one of the risk factors for coronary heart disease. The improvement of dyslipidemia can prevent or reverse the progression of atherosclerotic lesions, and can sig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/192A61P3/06A61K31/185
Inventor 秦献辉于多王文艳王燕李华戴成祥陈光亮徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com